Combination with 5-fluorouracil, methyl-CCNU and beta-2-deoxythioguanosine in advanced colo-rectal adenocarcinoma.
D000230:Adenocarcinoma / Q000188:drug therapy*; D000328:Adult; D000368:Aged; D003110:Colonic Neoplasms / Q000188:drug therapy*; D003853:Deoxyribonucleosides / Q000009:adverse effects / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D005472:Fluorouracil / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D009607:Nitrosourea Compounds / Q000627:therapeutic use*; D012004:Rectal Neoplasms / Q000188:drug therapy*; D012075:Remission, Spontaneous; D012673:Semustine / Q000009:adverse effects / Q000627:therapeutic use*; D013872:Thionucleosides / Q000009:adverse effects / Q000627:therapeutic use*; D013921:Thrombocytopenia / Q000139:chemically induced; D013997:Time Factors; D014839:Vomiting / Q000139:chemically induced
D003853:Deoxyribonucleosides; D009607:Nitrosourea Compounds; D013872:Thionucleosides; D012673:Semustine; D005472:Fluorouracil